双佐剂包被的破伤风类毒素马匹免疫试验

为提高破伤风免疫马匹的血浆抗体效价,应用不同佐剂配制TT抗原,进行马匹超免疫比较研究;采用FIA和植物油双佐剂包被与单佐剂包被的TT抗原,注射马匹进行超免疫,比较三组血浆的效价;结果显示,双佐剂抗原较单佐剂的免疫效果好,但可能对马匹刺激较强,有待调整注射剂量和免疫程序。     

细胞工程

900623 分泌抗口蹄疫病毒亚洲Ⅰ型的单克隆抗体的杂交瘤细胞株[英]/Butchaiah, G. …∥ Acta Virol.-1989,33(2).-121～130[译自DBA,1989,8(15),89-09176] 将伍合在弗氏完全佐剂的20～30μg口蹄疫病毒(FMDV)抗原经皮下或皮内免疫5～7周龄的BALB/c小鼠,然后,在第4和第12周再用伍合在弗氏不完全佐剂中的等量的抗原经皮下加强注射2次。4周     

金黄色葡萄球菌特异性卵黄抗体的制备及其影响因素

目的:考察金黄色葡萄球菌特异性卵黄抗体制备过程中的影响因素.方法:以灭活的金黄色葡萄球菌为抗原,采用不同的浓度(108cfu/mL,109cfu/mL,1010cfu/mL)、在不同免疫佐剂(商品弗氏佐剂和自制弗氏佐剂)作用下,对不同日龄(120天和300天)的蛋鸡进行免疫.免疫后收集鸡蛋,蛋黄用6倍体积水稀释,采用ELISA法测定抗体效价.结果:抗原浓度为109cfu/mL所得抗体效价最高;免疫120日龄蛋鸡获得抗体效价高于免疫300日龄蛋鸡所得抗体效价;在抗原浓度和蛋鸡日龄相同的情况下,商品弗氏佐剂比自制具有更好的免疫增强作用.结论:特异性卵黄抗体制备受多种因素的影响,抗原浓度、蛋鸡日龄、佐剂质量均对卵黄中特异性抗体水平有影响.     

补体C3对大肠杆菌疫苗的免疫增强作用

从SPF鸡血清中分离纯化C3,用戊二醛将其与大肠杆菌抗原连接,免疫注射SPF鸡;对照组鸡免疫注射弗氏完全佐剂大肠杆菌疫苗。分别在免疫后的第2、3、4、5、6、7、8、9周采血,用ELISA方法测定血清中的抗体含量,同时测定血清中总补体活性。结果表明,免疫后3周,弗氏佐剂大肠杆菌疫苗诱导鸡体产生的抗体效价高于C3佐剂疫苗组,但至第4周,弗氏佐剂疫苗组的抗体水平达到高峰(OD值=0.270±0.004),然后迅速下降,到第9周降至0.200±0.005,而C3疫苗组鸡免疫后的抗体水平持续上升,从免疫后第2周的0.098±0.003上升到第8周的0.275±0.002。证明C3能够促进免疫记忆细胞的产生,并能够使细菌抗原给予免疫细胞持续稳定的刺激,从而使鸡体维持高水平抗体的时间延长。研究结果为研制有效的家禽细菌性疫苗提供了理论依据。     

ISA 61 VG佐剂增强单核细胞增生李斯特氏菌灭活疫苗的保护性免疫应答

单核细胞增生李斯特氏菌(Listeria monocytogenes,Lm)是重要的人兽共患李斯特氏菌病的致病菌,疫苗免疫是预防该病原菌感染的有效手段之一。本研究研制了添加矿物油佐剂MontanideTM ISA61VG的新型灭活细菌疫苗,并对其安全性和免疫应答特性进行了研究。结果表明,ISA 61 VG佐剂疫苗具有较好的安全性;诱导小鼠产生的抗李斯特氏菌溶血素O抗体滴度以及IgG2a/IgG1比值显著高于无佐剂免疫组;在致死剂量Lm攻毒下,能对小鼠提供100%的免疫保护。因此,ISA 61VG佐剂能显著增强灭活疫苗诱导宿主产生体液免疫和细胞免疫应答的能力,从而提高灭活疫苗的保护性免疫应答作用,是预防人和动物Lm感染的潜在疫苗候选株。     

汉滩病毒核蛋白CTL表位肽联合不同免疫佐剂的免疫学特性研究

目的:研究汉滩病毒(HTNV)核蛋白细胞毒性T淋巴细胞(CTL)表位肽联合不同免疫佐剂免疫C57BL/6小鼠后的免疫学特性,确立一种免疫效果良好的多肽免疫C57BL/6小鼠方案。方法:分别用氢氧化铝、弗氏佐剂和脂质体作为免疫佐剂与汉滩病毒核衣壳蛋白上的CTL表位肽段混合,经皮下注射免疫C57BL/6小鼠,共免疫3次,每次间隔2周;免疫结束后分离小鼠脾细胞,并分别采用ELISPOT和CTL杀伤试验进行检测。结果:HTNV核蛋白CTL表位肽联合弗氏佐剂加脂质体组小鼠脾细胞分泌IFN-γ能力和CTL杀伤能力优于其他各实验组(P0.01)。结论:HTNVCTL表位肽联合弗氏佐剂加脂质体免疫C57BL/6小鼠效果最佳,可为HTNV多肽疫苗的免疫策略提供参考。     

抗绿脓杆菌外毒素 A 血浆的研制

试验制备了抗绿脓杆菌外毒素－Ａ血浆,使用马匹免疫抗原为精制ＰＡ－１０３菌株的外毒素－Ａ。抗血浆效价第一程采血达到了２０８８单位／ｍｌ,第三程采血达到５１８６单位／ｍｌ。     

不同佐剂对人乳头瘤病毒16型L2E7E6蛋白免疫效果的影响

目的:研究CpG佐剂、弗氏佐剂、聚肌胞苷酸佐剂及左旋咪唑、西米替丁作为佐剂对人乳头瘤病毒16型L2E7E6融合蛋白在小鼠体内产生的免疫效果的影响。方法:以单独蛋白组、蛋白加各佐剂组分别肌肉注射免疫C57BL/6小鼠,检测不同佐剂诱发小鼠产生的体液免疫和细胞免疫应答水平,并观察其对小鼠肿瘤生长的抑制作用。结果:各免疫组均能检测到高滴度的抗L2、E7、E6蛋白IgG抗体(以IgG1为主),其中弗氏佐剂能显著提高E6蛋白的IgG和IgG1抗体水平和E7蛋白的IgG1抗体水平(P<0.05),CpG佐剂明显提高了E7蛋白的IgG2a抗体水平(P<0.01);而西米替丁佐剂则降低了E7抗原的IgG抗体水平(P<0.05);同时可以检测到CpG佐剂组能诱发小鼠产生针对E7、E6较强的细胞免疫反应,且能抑制70%的荷瘤小鼠肿瘤生长;此外弗氏佐剂与聚肌胞苷酸佐剂可产生较弱的针对E7肽的细胞免疫反应,能延缓荷瘤小鼠肿瘤形成时间,与单纯蛋白组相比差异显著(P<0.05)。结论:CpG佐剂、弗氏佐剂和聚肌胞苷酸佐剂都能提高人乳头瘤病毒16型L2E7E6融合蛋白的细胞免疫反应水平和抑制肿瘤生长能力,其中CpG佐剂效果较好,为促进该蛋白作为疫苗的研发提供了实验依据。     

树鼩IgG纯化鉴定及其多克隆抗体制备和检测

目的:比较两种抗体纯化方法在分离纯化树鼩IgG抗体的应用,制备抗IgG的多克隆抗体及检测。方法:采用两种商品化IgG抗体纯化试剂盒分离树鼩血清IgG抗体,采用SDS-PAGE和蛋白定量测定提纯IgG。以树鼩IgG作为抗原,与等量弗氏完全佐剂(第一次)、弗氏不完全佐剂(第二次)混合皮下注射免疫兔,对分离血清进行多克隆抗体纯化及Western Blot检测及定量分析。结果:两种方法均能有效分离纯化树鼩IgG,在经过Montage PROSEP-A试剂纯化后的IgG在纯度和含量方面均优于Protein A/G Matrix试剂。通过纯化后的树鼩IgG免疫兔制备的抗IgG抗体能有效识别树鼩IgG。结论:纯化的树鼩IgG具有良好免疫原性,由此制备的抗体具有高度特异性。研究结果为利用树鼩作为实验动物提供了必要的实验基础。     

猪圆环病毒2型Cap蛋白在大肠杆菌中的可溶性表达及在小鼠体内免疫特性研究

猪圆环病毒2型(PCV2)Cap蛋白基因是该病毒基因工程疫苗的重要目的基因,但其在大肠杆菌表达系统中的表达产物通常以包涵体形式存在,影响其作为亚单位疫苗使用的免疫保护作用。将ORF2基因密码子改造为大肠杆菌偏爱的密码子,或构建MPG与ORF2基因融合,分别克隆至表达载体pET28a,再转化至大肠杆菌BL21(DE3),经IPTG诱导表达。SDS-PAGE和Western blot结果证实改造后的PCV2 Cap蛋白基因实现了可溶性表达。将上述两种重组蛋白纯化后,分别与GEL01、ISA206或ISA15A三种佐剂混合配制疫苗,小鼠免疫保护试验结果证明,以GEL01为佐剂的两免疫组PCV2 ELISA抗体和中和抗体水平最高。攻毒试验结果显示,除ISA15A组外,其他各免疫组脾脏中 PCV2 含量都显著低于非免疫对照组,表明两种重组蛋白与佐剂GEL01和ISA206制成的疫苗可诱导产生一定水平的免疫保护作用,为PCV2亚单位疫苗的研制奠定了基础。     

Trichinella spiralis: Immune response and protective immunity elicited by recombinant paramyosin formulated with different adjuvants

Our previous studies showed that immunization with recombinant paramyosin from Trichinella spiralis (rTs-Pmy) formulated with Freund’s adjuvant significantly reduced larval burden in mice after T. spiralis larval challenge. Since Freund’s adjuvant is toxic and not a suitable adjuvant for clinical vaccine trials, we evaluated the ability of the adjuvants Montanide ISA206 and ISA720 to stimulate immune responses during rTs-Pmy immunization and to enhance protective immunity. The results revealed that immunization of BALB/c mice with rTs-Pmy formulated with either ISA206 or ISA720 triggered Th1 and Th2 immune responses similar to those produced by the conventional Freund’s adjuvant formulation and also provided a similar level of protection against T. spiralis larval challenge. This indicates that the recombinant Ts-Pmy formulated with Montanide ISA206 or ISA720 may be an effective and safety vaccine strategy for trichinellosis.     

Protective immune response to 16 kDa immunoreactive recombinant protein encoding the C-terminal VP1 portion of Foot and Mouth Disease Virus type Asia 1.

Recombinant protein of Foot and Mouth Disease Virus (FMDV) type Asia 1 corresponding to the C-terminal half of VP1 was expressed in Escherichia coli. As an alternative to the synthetic peptide, this selected C-terminal region was used as a protein vaccine in guinea pigs in order to study the immune response with various adjuvant formulations: immune stimulatory complexes (ISCOMs), Montanide ISA 206, Freund's incomplete adjuvant (FIA), lipopolysaccharide (LPS) and cytokine mixture. A primary dose of 40 microg/animal followed by a booster of the same dose was injected after a 21-day interval. The sera were collected at intervals of 21, 42 and 63 days after the booster. The humoral response to vaccine was monitored by sandwich enzyme-linked immunosorbent assay (ELISA) and a serum neutralization test (SNT). The guinea pig sera showed high titers both in ELISA and SNT, which could be protective. Further, irrespective of the adjuvant preparation used, the vaccine conferred protection against the challenge virus 105 days post-vaccination in 13 of 15 animals (86%). The results indicated that a combination of recombinant protein ISCOMs and Montanide ISA 206 would be a better choice for achieving early protective titers and longer lasting immunity and that the C-terminal half of the VP1 protein may be tried as a safe vaccine for secondary immunization.     

Validation of immunity induced by inactivated CCPP vaccine with different adjuvants

The study was conducted in the premises National Veterinary Institute (NVI) to validate the immunity induced by inactivated F38 antigen adjuvated with saponin and Montanide ISA 50 and combined with and without anthrax vaccine.Post-inoculation reactions; pyrogenic effects, safety and inocuity of the vaccines were assessed. Increased body temperature and local edematous reactions were seen in animals inoculated with saponin adjuvated CCPP vaccine (100%) while 20% of the goats in ISA 50 adjuvated group showed local reaction. Sera collected from day 0 to 10th week were tested to assess the sero-conversion using monoclonal antibody based B-ELISA technique. Saponin adjuvated groups, in both monovalent CCPP and in the combined CCPP with anthrax vaccine showed a higher mean percentage of inhibition value as compared with ISA 50 adjuvated vaccine.After 8 months of post vaccination, contact challenge trial was conducted in 66 experimentally vaccinated and 20 negative control goats combined with 15 actively CCPP sick goats. Various clinical signs were recorded daily, autopsy was done on died goats and the live goats were sacrificed after 2 months of contact. The side by side samples from thoracic exudates, lung and mediastinal and bronchial lymph nodes were collected from goats shown to have developed indicative CCPP lesion for isolation and F38 antigen detection.The present experimental study indicated that application of inactivated and adjuvated CCPP vaccine significantly reduced the morbidity and development of lesions (P < 0.001). Among vaccinated groups CCPP + anthrax + saponin showed better protection, with low rate of nasal discharge and cough at 33% and 28.6%, respectively, and protection level of 94.1% from death and 65% from lung lesion development. However, the variation in protection among the vaccinated groups was not significant (P > 0.05).These findings disclosed that inactivated CCPP vaccine adjuvated with saponin and ISA 50 significantly reduce morbidity and mortality of goats due to CCPP and also indicated the importance of utilization of ISA 50 as alternative adjuvant to minimize post-vaccinal reactions encountered in use of saponin as adjuvant.     

An evaluation of several adjuvant emulsion regimens for the production of polyclonal antisera in rabbits.

Emulsion adjuvants have been used for production of polyclonal antisera in rabbits (Oryctolagus cunniculi) for decades. Complete Freund's adjuvant has a reputation as a very effective immunoenhancer, but adverse physiological effects, including fever, inflammation and sterile abscess formation, have prompted a search for alternatives to complete Freund's. In this study, we quantitatively compared five adjuvant regimens: (a) a primary inoculation with complete Freund's followed by three boosts with incomplete Freund's; (b) four serial inoculations of incomplete Freund's adjuvant augmented with 6-bromoguanisine; (c) four serial inoculations with RIBI's MPL + TDM + CWS adjuvant emulsion; (d) four serial inoculations with Montanide ISA 50 emulsion; and (e) four serial inoculations with Montanide ISA 70 emulsion. We chose a small (12 amino acid) chain polypeptide coupled to bovine serum albumin as our test antigen. When compared, no system could be seen to be significantly better than a regimen of a primary immunization with complete Freund's adjuvant followed by serial reimmunization with incomplete Freund's adjuvant. The commercially available RIBI adjuvant produced significantly lower antibody levels, while other systems produced essentially equivalent levels. With all five adjuvants, antibody quantities plateaued after the second injection and further immunization did not increase titers significantly. Boost injections did yield greater intradermal tissue reaction than primary inoculations, and intramuscular inoculum volumes of 0.4 cc caused chronic lesions still detectable by the gross necropsy 2 weeks after the final injection.     

Modulation of Antibody Responses against Gnathostoma spinigerum in Mice Immunized with Crude Antigen Formulated in CpG Oligonucleotide and Montanide ISA720

This study aimed to investigate the antibody responses in mice immunized with Gnathostoma spinigerum crude antigen (GsAg) incorporated with the combined adjuvant, a synthetic oligonucleotide containing unmethylated CpG motif (CpG ODN 1826) and a stable water in oil emulsion (Montanide ISA720). Mice immunized with GsAg and combined adjuvant produced all antibody classes and subclasses to GsAg except IgA. IgG2a/2b/3 but not IgG1 subclasses were enhanced by immunization with CpG ODN 1826 when compared with the control groups immunized with non-CpG ODN and Montanide ISA or only with Montanide ISA, suggesting a biased induction of a Th1-type response by CpG ODN. After challenge infection with live G. spinigerum larvae, the levels of IgG2a/2b/3 antibody subclasses decreased immediately and continuously, while the IgG1 subclass remained at high levels. This also corresponded to a continuous decrease of the IgG2a/IgG1 ratio after infection. Only IgM and IgG1 antibodies, but not IgG2a/2b/3, were significantly produced in adjuvant control groups after infection. These findings suggest that G. spinigerum infection potently induces a Th2-type biased response.